Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.

[1]  C. Tangen,et al.  SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Tannock,et al.  A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Saad,et al.  Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[5]  Mohammad H. Rashid,et al.  Intermittent androgen deprivation therapy for prostate cancer. , 2004, The oncologist.

[6]  P. Ell,et al.  Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. , 2004, Urology.

[7]  E. Small,et al.  Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Morote,et al.  Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. , 2003, European urology.

[9]  M. Wirth,et al.  Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. , 2003, European urology.

[10]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Parmar,et al.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). , 2003, Journal of the National Cancer Institute.

[12]  C. Higano.  Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. , 2003, Urologic oncology.

[13]  I. Tannock,et al.  Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Matthew R. Smith.  Management of treatment-related osteoporosis in men with prostate cancer. , 2003, Cancer treatment reviews.

[15]  J. Eastham,et al.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. , 2003, The Journal of urology.

[16]  M. Maricic,et al.  Osteoporosis in men. , 2003, American family physician.

[17]  R. Autorino,et al.  External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life. , 2003, Oncology reports.

[18]  J. Nelson,et al.  Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Matthew R. Smith.  Diagnosis and management of treatment‐related osteoporosis in men with prostate carcinoma , 2003, Cancer.

[20]  Jonathan R Green,et al.  Antitumor effects of bisphosphonates , 2003, Cancer.

[21]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[22]  Matthew R. Smith.  Osteoporosis during androgen deprivation therapy for prostate cancer. , 2002, Urology.

[23]  E. Small,et al.  Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. , 2002, The Journal of urology.

[24]  A. Hofman,et al.  Bone mineral density and mortality in elderly men and women: the Rotterdam Study. , 2002, Bone.

[25]  F. Saad,et al.  The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate , 2002, Cancer investigation.

[26]  C. Chesnut,et al.  Perspective: Reconsidering the Effects of Antiresorptive Therapies in Reducing Osteoporotic Fracture , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  O. Johnell,et al.  Mortality, Morbidity, and Assessment of Fracture Risk in Male Osteoporosis , 2001, Calcified Tissue International.

[28]  P. Kantoff,et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. , 2001, The New England journal of medicine.

[29]  P. Ross,et al.  The Assessment of Bone Mass in Men , 2001, Calcified Tissue International.

[30]  P. de Souza,et al.  The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade , 2001, Cancer.

[31]  A. Jakimiuk,et al.  Vertebral fractures: a hidden problem of osteoporosis. , 2001, Medical science monitor : international medical journal of experimental and clinical research.

[32]  S. Malkowicz.  The role of diethylstilbestrol in the treatment of prostate cancer. , 2001, Urology.

[33]  P. Kantoff,et al.  Low bone mineral density in hormone‐naïve men with prostate carcinoma , 2001, Cancer.

[34]  R. Parker,et al.  Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. , 2001, The Journal of clinical endocrinology and metabolism.

[35]  M. Giganti,et al.  A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer , 2001, European Journal of Nuclear Medicine.

[36]  R. Coleman,et al.  The management of bone metastases. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  A. Furuta,et al.  Incidence of bone fracture in patients receiving luteinizing hormone‐releasing hormone agonists for prostate cancer , 2000, BJU international.

[38]  G. Andriole,et al.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.

[39]  A. Lipton,et al.  Biochemical markers and skeletal metastases , 2000, Cancer.

[40]  J. Pfeilschifter,et al.  Osteoporosis due to cancer treatment: pathogenesis and management. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  I. Fourneau,et al.  Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures. , 1998, Acta chirurgica Belgica.

[42]  T. Diamond,et al.  The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma , 1998, Cancer.

[43]  H. Daniell.  Osteoporosis after orchiectomy for prostate cancer. , 1997, The Journal of urology.

[44]  L. Melton,et al.  Age-related hip fractures in men: Clinical spectrum and short-term outcomes , 1995, Osteoporosis International.

[45]  J. Kaufman.  Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: An overview , 1995, Clinical Rheumatology.

[46]  K. Carlström,et al.  Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens , 1995, Calcified Tissue International.

[47]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[48]  D. Baylink,et al.  Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. , 1989, The Journal of clinical endocrinology and metabolism.

[49]  R. Gill,et al.  Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .

[50]  J. Williams,et al.  High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate , 2006, International Urology and Nephrology.

[51]  D. Trump,et al.  Spinal cord compression in prostate cancer , 2005, Journal of Neuro-Oncology.

[52]  P. Jacobsen,et al.  The Caregiver Quality of Life Index–Cancer (CQOLC) scale: development and validation of an instrument to measure quality of life of the family caregiver of patients with cancer , 2004, Quality of Life Research.

[53]  Fred Saad,et al.  Role of bisphosphonates in prostate cancer. , 2004, European urology.

[54]  J. Waxman,et al.  How are we looking after prostate cancer? , 2003, QJM : monthly journal of the Association of Physicians.

[55]  Matthew R. Smith,et al.  Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. , 2003, Urology.

[56]  A. Heidenreich,et al.  Ibandronate in the treatment of prostate cancer associated painful osseous metastases , 2002, Prostate Cancer and Prostatic Diseases.

[57]  S. A. Jackson,et al.  The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across Canada , 2001, Osteoporosis International.

[58]  M. Terris,et al.  Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. , 2001, Urology.

[59]  P. V. Van Veldhuizen,et al.  Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. , 2000, The Journal of urology.